Fair 48°
Tag:

AstraZeneca

News
COVID-19: New Study Reveals How Prevalent Blood Clots Are With Pfizer, Moderna Vaccines COVID-19: New Study Reveals How Prevalent Blood Clots Are With Pfizer, Moderna Vaccines
Covid-19: New Study Reveals How Prevalent Blood Clots Are With Pfizer, Moderna Vaccines The ratio of people who have suffered from blood clots after receiving the Moderna or Pfizer COVID-19 vaccine is approximately the same as those who receive the AstraZeneca vaccine, according to a new study. Oxford University researchers found that the number of people who receive blood clots after getting vaccinated is approximately the same for all three vaccines, with four in one million people experiencing cerebral venous thrombosis (CVT) after getting the Pfizer or Moderna vaccine, compared to five in one million people for the AstraZeneca vaccine. The new study comes in the wake of A…

SHARE

by Zak Failla
News
COVID-19: Third Vaccine Approved For Use COVID-19: Third Vaccine Approved For Use
Covid-19: Third Vaccine Approved For Use A new COVID-19 vaccine that has proven effective in recent testing has been the third vaccine to gain approval. Developed by Oxford University in the United Kingdom by AstraZeneca and dubbed the “vaccine for the world,” the vaccine is nearly ready to begin distribution. Pfizer distributed the first COVID-19 vaccine, followed by Moderna's vaccine. Both are now been administered in the United States. Approximately 530,000 doses of the new vaccine are expected to be ready as soon as early next week, while the UK has reportedly ordered 100 million doses of the vaccine, which will allow them to…

SHARE

by Zak Failla
News
COVID-19: Pfizer Boasts Vaccine Candidate That's More Than 90% Effective COVID-19: Pfizer Boasts Vaccine Candidate That's More Than 90% Effective
Covid-19: Pfizer Boasts Vaccine Candidate That's More Than 90% Effective More reliable than the flu shot? Pfizer on Monday trumpeted a COVID-19 vaccine candidate as more than 90% effective – nearly three times better than the effectiveness of last season’s influenza vaccine. Pfizer said it hopes to have 50 million doses of the free vaccine ready by the end of this year and as many as 1.3 billion doses available next year to fight the deadly global pandemic. Two doses per person of BNT162b2 would be necessary, said the Manhattan-based drug maker, which teamed up with BioNTech of Germany to develop the booster. Pfizer plans to ask the federal Food and Drug Admini…

SHARE

by Jerry DeMarco